Cargando…

Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India

AIM: Complimentary use of Liver directed therapies (LDTs) with systemic chemotherapy has improved oncologic outcomes in colorectal liver metastasis (CRLM). We analysed institutional results of multimodality management. METHODS: Retrospective analysis of prospectively maintained database of CRLM pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Patkar, Shraddha, Chopde, Amit, Shetty, Nitin, Kulkarni, Suyash, Gala, Kunal Bharat, Chandra, Daksh, Ramaswamy, Anant, Ostwal, Vikas, Goel, Mahesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073418/
https://www.ncbi.nlm.nih.gov/pubmed/37035190
http://dx.doi.org/10.3389/fonc.2023.1073311
_version_ 1785019559227424768
author Patkar, Shraddha
Chopde, Amit
Shetty, Nitin
Kulkarni, Suyash
Gala, Kunal Bharat
Chandra, Daksh
Ramaswamy, Anant
Ostwal, Vikas
Goel, Mahesh
author_facet Patkar, Shraddha
Chopde, Amit
Shetty, Nitin
Kulkarni, Suyash
Gala, Kunal Bharat
Chandra, Daksh
Ramaswamy, Anant
Ostwal, Vikas
Goel, Mahesh
author_sort Patkar, Shraddha
collection PubMed
description AIM: Complimentary use of Liver directed therapies (LDTs) with systemic chemotherapy has improved oncologic outcomes in colorectal liver metastasis (CRLM). We analysed institutional results of multimodality management. METHODS: Retrospective analysis of prospectively maintained database of CRLM patients managed with LDT including surgical resection, Ablation, Transarterial chemoembolization (TACE) or Transarterial radioembolization (TARE) between November 2011 to March 2020. Management plan was decided in multidisciplinary meeting. Resectable tumours underwent surgical resection or ablation or both in some cases. Borderline resectable or unresectable disease was treated with down staging chemotherapy or TACE/TARE followed by resection or ablation. All patients received adjuvant chemotherapy. Factors influencing survival were analysed. RESULTS: Out of total 375 patients, surgery alone was done in 191 (50.93%) patients while surgery with other LDT in 26 patients (6.93%). Ablation alone was done in 100 (26.66%) whereas TACE/TARE were done as standalone treatment in 21 (5.6%) and 7 (1.86%) patients respectively. TACE + ablation was done in 28 (7.46%) and TARE + ablation was done in 2(0.53%) patients.5-year Overall Survival(OS) was 49.8% while Event free survival(EFS) was 21.4%. The median OS and EFS for surgical group was significantly better than non-surgical group (78 V/s 39 months; p<0.05 and 20 V/s 15 months p <0.005). The resectable (78 months) group had better median OS as compared to borderline resectable and Unresectable group (39 months and 29 months). Male gender, resectable disease and surgical intervention were associated with improved OS. CONCLUSION: Although surgery remains the mainstay of treatment, complementary use of non-surgical LDT with systemic therapy offers possibility of good outcomes in advanced liver limited disease. Our experience highlights the impact of multidisciplinary care in optimizing CRLM treatment.
format Online
Article
Text
id pubmed-10073418
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100734182023-04-06 Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India Patkar, Shraddha Chopde, Amit Shetty, Nitin Kulkarni, Suyash Gala, Kunal Bharat Chandra, Daksh Ramaswamy, Anant Ostwal, Vikas Goel, Mahesh Front Oncol Oncology AIM: Complimentary use of Liver directed therapies (LDTs) with systemic chemotherapy has improved oncologic outcomes in colorectal liver metastasis (CRLM). We analysed institutional results of multimodality management. METHODS: Retrospective analysis of prospectively maintained database of CRLM patients managed with LDT including surgical resection, Ablation, Transarterial chemoembolization (TACE) or Transarterial radioembolization (TARE) between November 2011 to March 2020. Management plan was decided in multidisciplinary meeting. Resectable tumours underwent surgical resection or ablation or both in some cases. Borderline resectable or unresectable disease was treated with down staging chemotherapy or TACE/TARE followed by resection or ablation. All patients received adjuvant chemotherapy. Factors influencing survival were analysed. RESULTS: Out of total 375 patients, surgery alone was done in 191 (50.93%) patients while surgery with other LDT in 26 patients (6.93%). Ablation alone was done in 100 (26.66%) whereas TACE/TARE were done as standalone treatment in 21 (5.6%) and 7 (1.86%) patients respectively. TACE + ablation was done in 28 (7.46%) and TARE + ablation was done in 2(0.53%) patients.5-year Overall Survival(OS) was 49.8% while Event free survival(EFS) was 21.4%. The median OS and EFS for surgical group was significantly better than non-surgical group (78 V/s 39 months; p<0.05 and 20 V/s 15 months p <0.005). The resectable (78 months) group had better median OS as compared to borderline resectable and Unresectable group (39 months and 29 months). Male gender, resectable disease and surgical intervention were associated with improved OS. CONCLUSION: Although surgery remains the mainstay of treatment, complementary use of non-surgical LDT with systemic therapy offers possibility of good outcomes in advanced liver limited disease. Our experience highlights the impact of multidisciplinary care in optimizing CRLM treatment. Frontiers Media S.A. 2023-03-22 /pmc/articles/PMC10073418/ /pubmed/37035190 http://dx.doi.org/10.3389/fonc.2023.1073311 Text en Copyright © 2023 Patkar, Chopde, Shetty, Kulkarni, Gala, Chandra, Ramaswamy, Ostwal and Goel https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Patkar, Shraddha
Chopde, Amit
Shetty, Nitin
Kulkarni, Suyash
Gala, Kunal Bharat
Chandra, Daksh
Ramaswamy, Anant
Ostwal, Vikas
Goel, Mahesh
Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India
title Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India
title_full Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India
title_fullStr Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India
title_full_unstemmed Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India
title_short Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India
title_sort multimodality liver directed treatment for colorectal liver metastasis: array of complementary options can improve outcomes - a single centre experience from india
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073418/
https://www.ncbi.nlm.nih.gov/pubmed/37035190
http://dx.doi.org/10.3389/fonc.2023.1073311
work_keys_str_mv AT patkarshraddha multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia
AT chopdeamit multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia
AT shettynitin multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia
AT kulkarnisuyash multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia
AT galakunalbharat multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia
AT chandradaksh multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia
AT ramaswamyanant multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia
AT ostwalvikas multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia
AT goelmahesh multimodalityliverdirectedtreatmentforcolorectallivermetastasisarrayofcomplementaryoptionscanimproveoutcomesasinglecentreexperiencefromindia